Germany · Delayed Price · Currency is EUR Autolus Therapeutics Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 754 |
| CEO | Christian Itin |
Contact Details
Address: The Mediaworks London, W12 7FP United Kingdom | |
| Phone | 44 20 3829 6230 |
| Website | autolus.com |
Stock Details
| Ticker Symbol | 6A3A |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Itin | Chief Executive Officer |
| Robert Dolski | Chief Financial Officer |
| Christopher Vann | Chief Operating Officer |
| Olivia Manser | Head of Investor Relations |